Lantheus (NASDAQ:LNTH) Shares Down 4.6% - Time to Sell?

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) shares traded down 4.6% during trading on Wednesday . The company traded as low as $100.01 and last traded at $99.85. 106,252 shares changed hands during mid-day trading, a decline of 89% from the average session volume of 927,199 shares. The stock had previously closed at $104.62.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. JMP Securities reissued a "market outperform" rating and issued a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. StockNews.com cut Lantheus from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. The Goldman Sachs Group assumed coverage on Lantheus in a research report on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price target on the stock. Finally, Truist Financial boosted their price target on Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $132.86.

Remove Ads

Lantheus Trading Up 1.8 %

The company has a market capitalization of $6.92 billion, a PE ratio of 16.82 and a beta of 0.38. The business's fifty day moving average is $92.07 and its two-hundred day moving average is $96.77.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). The company had revenue of $391.11 million for the quarter, compared to analysts' expectations of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. As a group, equities research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Insider Buying and Selling at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the company's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now directly owns 33,207 shares in the company, valued at $3,146,695.32. This represents a 2.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Mary Anne Heino sold 53,107 shares of the company's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares of the company's stock, valued at $41,551,645.65. This trade represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.50% of the company's stock.

Institutional Investors Weigh In On Lantheus

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Janus Henderson Group PLC increased its stake in Lantheus by 72.7% in the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock worth $554,583,000 after buying an additional 2,610,118 shares in the last quarter. Farallon Capital Management LLC raised its holdings in Lantheus by 79.9% during the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock valued at $475,590,000 after acquiring an additional 2,361,000 shares during the period. Geode Capital Management LLC raised its holdings in Lantheus by 2.0% during the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider's stock valued at $184,798,000 after acquiring an additional 32,551 shares during the period. T. Rowe Price Investment Management Inc. raised its holdings in Lantheus by 40.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock valued at $135,025,000 after acquiring an additional 435,445 shares during the period. Finally, Reinhart Partners LLC. raised its holdings in Lantheus by 9.9% during the fourth quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider's stock valued at $122,280,000 after acquiring an additional 123,282 shares during the period. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.